CN1289086C - 抗疟治疗药物的新用途 - Google Patents

抗疟治疗药物的新用途 Download PDF

Info

Publication number
CN1289086C
CN1289086C CNB028267923A CN02826792A CN1289086C CN 1289086 C CN1289086 C CN 1289086C CN B028267923 A CNB028267923 A CN B028267923A CN 02826792 A CN02826792 A CN 02826792A CN 1289086 C CN1289086 C CN 1289086C
Authority
CN
China
Prior art keywords
virus
rhinovirus
purposes
antimalarial
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028267923A
Other languages
English (en)
Chinese (zh)
Other versions
CN1612735A (zh
Inventor
劳伦·夏鲁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
APT Pharmaceuticals LLC
Original Assignee
APT Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by APT Pharmaceuticals LLC filed Critical APT Pharmaceuticals LLC
Publication of CN1612735A publication Critical patent/CN1612735A/zh
Application granted granted Critical
Publication of CN1289086C publication Critical patent/CN1289086C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB028267923A 2001-11-09 2002-11-12 抗疟治疗药物的新用途 Expired - Fee Related CN1289086C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34587201P 2001-11-09 2001-11-09
US60/345,872 2001-11-09

Publications (2)

Publication Number Publication Date
CN1612735A CN1612735A (zh) 2005-05-04
CN1289086C true CN1289086C (zh) 2006-12-13

Family

ID=23356861

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028267923A Expired - Fee Related CN1289086C (zh) 2001-11-09 2002-11-12 抗疟治疗药物的新用途

Country Status (9)

Country Link
US (1) US20040167162A1 (https=)
EP (1) EP1450803A4 (https=)
JP (1) JP2005512998A (https=)
CN (1) CN1289086C (https=)
AU (1) AU2002363443B2 (https=)
CA (1) CA2466338C (https=)
IL (1) IL161821A0 (https=)
MX (1) MXPA04004393A (https=)
WO (1) WO2003039546A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7084157B2 (en) * 2002-05-17 2006-08-01 Rajeev Raut Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation
AU2003292489A1 (en) * 2003-03-27 2004-10-18 Council Of Scientific And Industrial Research Ring-substituted 8-aminoqunoline derivates as antimalarial agents
US20070134596A1 (en) * 2005-12-08 2007-06-14 Adrian Lungu Photosensitive printing element having nanoparticles and method for preparing the printing element
WO2007098047A2 (en) * 2006-02-16 2007-08-30 The Mclean Hospital Corporation Methods and compositions for the treatment of parkinson's disease
KR101067443B1 (ko) * 2009-06-23 2011-09-27 여오영 하이드록시클로로퀸을 함유하는 치핵 치료를 위한 국소투여용 주사제 조성물
CN103027915A (zh) * 2011-09-29 2013-04-10 中国医学科学院基础医学研究所 氯喹治疗和氯丙嗪预防肺感染和损伤的用途
CN103705516B (zh) * 2013-12-11 2016-01-06 武汉威立得生物医药有限公司 氯喔星在制备治疗或预防流感病毒感染的药物中的应用
KR101828553B1 (ko) * 2016-04-15 2018-02-13 한국화학연구원 신규한 벤조싸이오펜 유도체, 이의 약학적으로 허용 가능한 염 또는 이의 광학 이성질체, 이의 제조방법 및 이를 유효성분으로 함유하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물
WO2018002153A1 (en) * 2016-06-28 2018-01-04 Assistance Publique - Hopitaux De Paris Hycanthone derivatives and primaquine derivatives for use in the prevention and/or the treatment of disorders associated to gammaherpesvirus
CN111658648A (zh) * 2020-02-03 2020-09-15 中国人民解放军军事科学院军事医学研究院 4-氨基喹啉类化合物在治疗冠状病毒感染方面的应用
US20210244705A1 (en) * 2020-02-07 2021-08-12 Centre For Digestive Diseases Therapeutic compositions, products of manufacture and methods for ameliorating or preventing coronavirus infection
CN114657149B (zh) * 2020-02-16 2023-10-20 北京化工大学 西拉菌素在制备治疗冠状病毒感染性疾病的药物的用途
US11638722B2 (en) 2020-03-25 2023-05-02 Therapeutica Borealis Oy C/O Avance Attorneys Ltd. Medicine for Covid-19 and treatment
US11007187B1 (en) * 2020-03-25 2021-05-18 Therapeutica Borealis Oy Medicine for Covid-19 and treatment
US11278602B2 (en) 2020-03-25 2022-03-22 Therapeutica Borealis Oy Medicine for Covid-19 and treatment
WO2021191496A1 (en) * 2020-03-25 2021-09-30 Therapeutica Borealis Oy Medicine for covid-19 and treatment
WO2021204717A1 (en) * 2020-04-06 2021-10-14 Oxandia Ltd Aminoquinolines for treating coronavirus infections
EP3892275A1 (en) * 2020-04-08 2021-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Aerosolization of hcq or its metabolites for the treatment of lung infections
EP4135673A4 (en) * 2020-04-14 2024-05-08 Glanis Pharmaceuticals, Inc. TRANSDERMAL AND/OR TOPICAL ADMINISTRATION SYSTEM COMPRISING HYDROXYCHLOROQUINE AND/OR CHLOROQUINE
WO2021216759A1 (en) * 2020-04-21 2021-10-28 Noam Cohen Quinine and its use to generate innate immune response
CN115955965A (zh) * 2020-04-24 2023-04-11 拓比利亚欧斯特有限公司 用于治疗、改善或预防微生物感染的制造产品和方法
CN115515587A (zh) * 2020-04-27 2022-12-23 免疫学有限公司 用于治疗冠状病毒感染的6’-甲氧基辛可宁-9-醇类
WO2021217574A1 (en) * 2020-04-30 2021-11-04 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Treatment or prevention of coronaviridae infection
EP4210829A1 (en) * 2020-09-14 2023-07-19 Philip Morris Products S.A. Pharmaceutical composition comprising hydroxychloroquine and uses thereof
DE102021000717A1 (de) * 2021-02-12 2022-08-18 Forschungszentrum Jülich GmbH Quinacrin als lnhibitor viraler Cysteinproteasen und/oder Serinproteasen
US20240391876A1 (en) * 2021-08-19 2024-11-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Quinacrine and derivatives thereof for treatment of viral infections
CN115869311A (zh) * 2022-12-30 2023-03-31 湖北工业大学 MefloquineHydrochloride在制备抗腺病毒ADV7药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181725A (en) * 1977-05-02 1980-01-01 The Regents Of The University Of Michigan Method for alleviating psoriasis
US4496549A (en) * 1983-01-17 1985-01-29 American Cyanamid Company Treatment of malaria with antibiotics
US5153202A (en) * 1988-06-30 1992-10-06 Davis Michael H Method of inhibiting the activity of human immuno deficiency virus (HIV) in vivo
US5376359A (en) * 1992-07-07 1994-12-27 Glaxo, Inc. Method of stabilizing aerosol formulations
US5827681A (en) * 1996-12-20 1998-10-27 University Technology Corporation Rapid detection and drug sensitivity of malaria
CA2372443C (en) * 1999-04-30 2010-07-13 Apt Pharmaceuticals, L.L.C. Local administration of anti-malarial agents for the treatment of inflammatory diseases

Also Published As

Publication number Publication date
CA2466338C (en) 2010-01-12
US20040167162A1 (en) 2004-08-26
EP1450803A4 (en) 2008-09-03
MXPA04004393A (es) 2005-09-12
EP1450803A1 (en) 2004-09-01
CN1612735A (zh) 2005-05-04
CA2466338A1 (en) 2003-05-15
WO2003039546A1 (en) 2003-05-15
HK1075619A1 (en) 2005-12-23
IL161821A0 (en) 2005-11-20
AU2002363443B2 (en) 2006-02-16
JP2005512998A (ja) 2005-05-12

Similar Documents

Publication Publication Date Title
CN1289086C (zh) 抗疟治疗药物的新用途
CN115362004B (zh) 1’-氰基取代的碳核苷类似物的吸入制剂
AU2002363443A1 (en) New uses for anti-malarial therapeutic agents
JP6827948B2 (ja) 呼吸器疾患の治療
KR102232625B1 (ko) 폐 병태의 치료를 위한 고침투 전구약물 조성물 및 그의 약제학적 조성물
JP2014525471A (ja) 咳および咳発作の治療
JP2023520229A (ja) 製剤
CA2575932A1 (en) Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
JP2002543122A (ja) 抗マラリア治療剤についての新規使用
CN1674939A (zh) 用于治疗呼吸性疾病、过敏性疾病、哮喘和copd的糖皮质激素与磷酸二酯酶－4抑制剂的新组合
AU2008259864C1 (en) Methods and compositions for administration of Oxybutynin
JP2023534723A (ja) コロナウイルス感染症の治療におけるベンフルメトール及びその誘導体の応用
CN1553801A (zh) 含三环5,6-二氢-9H-吡唑并(3,4-C)-1,2,4-三唑并(4,3-α)嘧啶的吸入组合物
US20240016786A1 (en) Glucosidase inhibitors for the treatment and prevention of pulmonary infections
WO2021204717A1 (en) Aminoquinolines for treating coronavirus infections
JP2023524064A (ja) ウイルス感染を治療又は予防するためのクロファジミン組成物及び方法
JP2013510838A (ja) 微生物感染症の治療
HK1075619B (en) New uses for anti-malarial therapeutic agents
CN104780921A (zh) Hcv的大环蛋白酶抑制剂、非核苷hcv抑制剂和利托那韦的组合
WO2011127538A1 (en) Compound for treatment of respiratory condition or disease
JP2016504358A (ja) オキシブチニンを投与するための方法および組成物
WO2024016639A1 (zh) 一种抗病毒感染的化合物及其制备方法和用途
CN1767827A (zh) 肺部疾病的治疗及/或预防剂
HK40084723B (zh) 1’-氰基取代的碳核苷类似物的吸入制剂
CN101631538A (zh) 用于治疗慢性阻塞性肺病的药物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1075619

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: APT PHARMACEUTICAL CO.,LTD.

Free format text: FORMER OWNER: LAOLUNJIALU

Effective date: 20051209

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20051209

Address after: Arizona, USA

Applicant after: APT Pharmaceutical Inc.

Address before: Wisconsin

Applicant before: Charous Lauren

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1075619

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20061213

Termination date: 20121112